PURPOSE: Importance of polymorphisms in NF-kappaB1 and NF-kappaBIalpha genes for melanoma risk, clinicopathological features and tumor progression is analyzed in Swedish melanoma patients. PATIENTS AND METHODS: Functional polymorphisms of NF-kappaB1 and NF-kappaBIalpha genes were examined in 185 melanoma patients and 438 tumor-free individuals. Associations of the polymorphisms with melanoma risk, age and pigment phenotypes of the patients and clinicopathological tumor characteristics were analyzed. DNAs were isolated from mononuclear cells of venous blood. Polymorphisms of the genes were genotyped by a PCR-RFLP technique, and transcription level of NF-kappaBIalpha was examined by a quantitative real-time reverse transcription PCR. RESULTS: Both ATTG insertion polymorphism of NF-kappaB1 and A to G polymorphism of NF-kappaBIalpha genes were correlated with melanoma risk, especially, in a combination of ATTG( 2 )/ATTGT(2) and GG. NF-kappaB1 ATTG(2)/ATTG(2) and NF-kappaBIalpha GG genotypes were associated with male gender and age >65 years (at diagnosis). Patients with ATTG(1)/ATTG(1 )genotype had thinner tumors and lower Clark levels at diagnosis. Frequency of ATTG(1)/ATTG(1) genotype was higher in patients with melanomas on intermittently sun-exposed pattern of the body andNF-kappaBIalpha GG was more frequent in the patients with melanomas at rarely exposed sites. There were no differences in the gene transcription level between patients with different NF-kappaBIalpha genotypes. CONCLUSION:NF-kappaB1 and NF-kappaBIalpha genes might be susceptible genes for melanoma risk and functional polymorphisms of these genes might be biological predictors for melanoma progression.
RCT Entities:
PURPOSE: Importance of polymorphisms in NF-kappaB1 and NF-kappaBIalpha genes for melanoma risk, clinicopathological features and tumor progression is analyzed in Swedish melanomapatients. PATIENTS AND METHODS: Functional polymorphisms of NF-kappaB1 and NF-kappaBIalpha genes were examined in 185 melanomapatients and 438 tumor-free individuals. Associations of the polymorphisms with melanoma risk, age and pigment phenotypes of the patients and clinicopathological tumor characteristics were analyzed. DNAs were isolated from mononuclear cells of venous blood. Polymorphisms of the genes were genotyped by a PCR-RFLP technique, and transcription level of NF-kappaBIalpha was examined by a quantitative real-time reverse transcription PCR. RESULTS: Both ATTG insertion polymorphism of NF-kappaB1 and A to G polymorphism of NF-kappaBIalpha genes were correlated with melanoma risk, especially, in a combination of ATTG( 2 )/ATTGT(2) and GG. NF-kappaB1 ATTG(2)/ATTG(2) and NF-kappaBIalpha GG genotypes were associated with male gender and age >65 years (at diagnosis). Patients with ATTG(1)/ATTG(1 )genotype had thinner tumors and lower Clark levels at diagnosis. Frequency of ATTG(1)/ATTG(1) genotype was higher in patients with melanomas on intermittently sun-exposed pattern of the body and NF-kappaBIalpha GG was more frequent in the patients with melanomas at rarely exposed sites. There were no differences in the gene transcription level between patients with different NF-kappaBIalpha genotypes. CONCLUSION: NF-kappaB1 and NF-kappaBIalpha genes might be susceptible genes for melanoma risk and functional polymorphisms of these genes might be biological predictors for melanoma progression.
Authors: C M Balch; S J Soong; J E Gershenwald; J F Thompson; D S Reintgen; N Cascinelli; M Urist; K M McMasters; M I Ross; J M Kirkwood; M B Atkins; J A Thompson; D G Coit; D Byrd; R Desmond; Y Zhang; P Y Liu; G H Lyman; A Morabito Journal: J Clin Oncol Date: 2001-08-15 Impact factor: 44.544
Authors: Markus Bredel; Denise M Scholtens; Ajay K Yadav; Angel A Alvarez; Jaclyn J Renfrow; James P Chandler; Irene L Y Yu; Maria S Carro; Fangping Dai; Michael J Tagge; Roberto Ferrarese; Claudia Bredel; Heidi S Phillips; Paul J Lukac; Pierre A Robe; Astrid Weyerbrock; Hannes Vogel; Steven Dubner; Bret Mobley; Xiaolin He; Adrienne C Scheck; Branimir I Sikic; Kenneth D Aldape; Arnab Chakravarti; Griffith R Harsh Journal: N Engl J Med Date: 2010-12-22 Impact factor: 91.245
Authors: Abdullateef A Alzolibani; Ahmed Settin; Ahmed Ali Ahmed; Hisham Ismail; Noor Elhefni; Ahmad A Al Robaee Journal: Int J Health Sci (Qassim) Date: 2015-01
Authors: James R Cerhan; Wen Liu-Mares; Zachary S Fredericksen; Anne J Novak; Julie M Cunningham; Neil E Kay; Ahmet Dogan; Mark Liebow; Alice H Wang; Timothy G Call; Thomas M Habermann; Stephen M Ansell; Susan L Slager Journal: Cancer Epidemiol Biomarkers Prev Date: 2008-11 Impact factor: 4.254
Authors: Ellen T Chang; Brenda M Birmann; Julie L Kasperzyk; David V Conti; Peter Kraft; Richard F Ambinder; Tongzhang Zheng; Nancy E Mueller Journal: Cancer Epidemiol Biomarkers Prev Date: 2009-02-17 Impact factor: 4.254
Authors: Kristin L White; Robert A Vierkant; Catherine M Phelan; Brooke L Fridley; Stephanie Anderson; Keith L Knutson; Joellen M Schildkraut; Julie M Cunningham; Linda E Kelemen; V Shane Pankratz; David N Rider; Mark Liebow; Lynn C Hartmann; Thomas A Sellers; Ellen L Goode Journal: BMC Cancer Date: 2009-06-06 Impact factor: 4.430